+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • ID: 4769301
  • Report
  • January 2019
  • Region: Global
  • 201 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abbvie Inc
  • AstraZeneca Plc
  • Can-Fite BioPharma Ltd
  • F Hoffman-La Roche Ltd
  • Gilead Science Inc
  • Pfizer Inc
  • MORE
Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Summary

The Rheumatoid Arthritis (RA) market is expected to grow from $23.3bn in 2017 to $27.8bn in 2027 across the eight major markets (US, France, Germany, Italy, Spain, the UK, Japan, and Australia) at a compound annual growth rate (CAGR) of 1.8%. Between 2017 and 2027, modest growth in the RA market will be driven primarily by the anticipated approval and launch of seven pipeline therapies.

Rheumatoid Arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time.

Over the last 20 years, the RA market has grown prodigiously with the introduction and continued development of biologic medicines. This includes blockbuster drugs such as Pfizer/Amgen’s Enbrel (etanercept) and AbbVie’s Humira (adalimumab), which in 2017, together claimed over 50% of the total RA market ($12.3bn).

However, in recent years, growth in the RA market has begun to slacken and will likely continue to slow as a result of biosimilar erosion. Over the forecast period, revenue from the biosimilar class is expected to increase from 1% to 22% of total sales, growing at a CAGR of 34.9%. The expansion of the small molecule JAK inhibitor class and other novel oral agents will play especially powerful roles in shaping the RA market of the future. During the forecast period, it is projected that throughout the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and Australia), the JAK inhibitor class will grow at a CAGR of 7.9%.

Although the RA market is fairly mature, KOLs emphasized that there is still room for the standard of care to improve. Of particular note are the unmet needs for earlier diagnosis and treatment of the disease, more cost-effective medications, personalized strategies for treatment of active disease, and a better-defined approach to de-escalation of disease-modifying antirheumatic drugs (DMARDs) during remission.

The latest report "Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027", reveal that although the RA market is expected to grow during the forecast period, this growth will be significantly tempered by biosimilar erosion.

Key Questions Answered
  • How will biosimilar uptake differ cross the 8MM?
  • What companies and drugs will be most affected by sales erosion from biosimilars?
  • What are the main unmet needs in the RA market?
  • How can the pharmaceutical industry address these needs?
  • To what degree will the therapies under development fulfill these unmet needs?
  • What are the main R&D trends in the RA market and which companies are leading the way?
  • Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?
Scope
  • Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global RA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global RA therapeutics market from 2017-2027.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbvie Inc
  • AstraZeneca Plc
  • Can-Fite BioPharma Ltd
  • F Hoffman-La Roche Ltd
  • Gilead Science Inc
  • Pfizer Inc
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary
2.1 Biosimilar Erosion Will Temper Sales Growth in the RA Market from 2017-2027
2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies
2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA patients
2.4 Pipeline JAK1 Inhibitors Are Best Equipped to Penetrate the Crowded RA Market
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms and Severity Classifications

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
5.6 Discussion

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 Australia

7 Competitive Assessment
7.1 Overview
7.2 Biosimilars in the RA Market

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Earlier Diagnosis and Treatment
8.3 Cost-Effective Therapies
8.4 Personalized Treatment Strategies
8.5 Improved Guidance on Treating RA Patients in Remission

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Portfolio Assessments

11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 Australia

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About the Author
12.8 Contact Us
12.9 Disclaimer

List of Tables
  • Table 1: RA: Key Metrics in the 8MM
  • Table 2: RA Disease Severity Classification
  • Table 3: Risk Factors and Comorbidities of RA
  • Table 4: 1987 ACR Diagnostic Criteria for RA
  • Table 5: Classification Criteria for Rheumatoid Arthritis - ACR 1987
  • Table 6: Classification Criteria for Rheumatoid Arthritis - ACR/EULAR 2010
  • Table 7: Treatment Guidelines for RA throughout the 8MM, 2018
  • Table 8: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials
  • Table 9: Country Profile - US
  • Table 10: Regional Profile - 5EU
  • Table 11: Country Profile - Japan
  • Table 12: Country Profile - Australia
  • Table 13: Leading Branded Treatments for RA, 2018
  • Table 14: Marketed Biosimilars for RA, 2018
  • Table 15: Pipeline Biosimilars for RA, 2018
  • Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2017
  • Table 17: AbbVie’s RA Portfolio Assessment, 2018
  • Table 18: Pfizer’s RA Portfolio Assessment, 2018
  • Table 19: Amgen’s RA Portfolio Assessment, 2018
  • Table 20: J&J’s RA Portfolio Assessment, 2018
  • Table 21: BMS’ RA Portfolio Assessment, 2018
  • Table 22: Roche/Genentech’s RA Portfolio Assessment, 2018
  • Table 23: Eli Lilly’s RA Portfolio Assessment, 2018
  • Table 24: UCB’s RA Portfolio Assessment, 2018
  • Table 25: Sanofi’s RA Portfolio Assessment, 2018
  • Table 26: Astellas’ RA Portfolio Assessment, 2018
  • Table 27: Gilead’s RA Portfolio Assessment, 2018
  • Table 28: Galapagos’ RA Portfolio Assessment, 2018
  • Table 29: R-Pharm’s RA Portfolio Assessment, 2018
  • Table 30: Taisho’s RA Portfolio Assessment, 2018
  • Table 31: Can-Fite’s RA Portfolio Assessment, 2018
  • Table 32: RA Market - Global Drivers and Barriers, 2017-2027
  • Table 33: Key Events Impacting Sales for RA in the US, 2017-2027
  • Table 34: RA Market - Drivers and Barriers in the US, 2017-2027
  • Table 35: Key Events Impacting Sales for RA in the 5EU, 2017-2027
  • Table 36: RA Market - Drivers and Barriers in the 5EU, 2017-2027
  • Table 37: Key Events Impacting Sales for RA in Japan, 2017-2027
  • Table 38: RA Market - Global Drivers and Barriers in Japan, 2017-2027
  • Table 39: Key Events Impacting Sales for RA in Australia, 2017-2027
  • Table 40: RA Market - Global Drivers and Barriers in Australia, 2017-2027
  • Table 41: Key Historical and Projected Launch Dates for RA
  • Table 42: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA
  • Table 43: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
  • Figure 1: Global Sales Forecast by Country for RA in 2017 and 2027
  • Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That the Author Expects to Be Licensed for the Treatment of RA During the Forecast Period
  • Figure 4: Overview of RA Pathogenesis and Pathophysiology
  • Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs
  • Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2017
  • Figure 7: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Men, Ages ≥18 Years, 2007 to 2027
  • Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Women, Ages ≥18 Years, 2007 to 2027
  • Figure 9: 8MM, Age-Standardized Total Prevalence of RA (%), Men, Ages ≥18 Years, 2007 to 2027
  • Figure 10: 8MM, Age-Standardized Total Prevalence of RA (%), Women, Ages ≥18 Years, 2007 to 2027
  • Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
  • Figure 12: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
  • Figure 13: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
  • Figure 14: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N, 2017
  • Figure 17: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N, 2017
  • Figure 20: 8MM, Diagnosed Prevalent Cases of RA By Severity, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 21: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 22: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, Ages ≥18 Years, N, 2017
  • Figure 23: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2017
  • Figure 24: General Treatment Algorithm for RA Patients
  • Figure 25: Physicians Reporting Prescription of Biosimilars to at Least 25%, 50%, or 75% of Their RA Patients Throughout the 8MM, 2018
  • Figure 26: Physicians Reporting Prescription of Biosimilars to at Least 50% of Their RA Patients Throughout the 5EU, 2018
  • Figure 27: Prescription of Etanercept, Infliximab, and Rituximab Biosimilars in Comparison to Reference Biologics Among 5EU Physicians, 2017
  • Figure 28: Unmet Needs and Opportunities in RA, 2018
  • Figure 29: Overview of the Development Pipeline in RA
  • Figure 30: Key Phase II/III Trials for the Promising Pipeline Agents That the Author Expects to Be Licensed for RA in the 8MM During the Forecast Period
  • Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents That the Author Expects to Be Licensed for the Treatment of RA During the Forecast Period, 2017-2027
  • Figure 32: Analysis of the Company Portfolio Gap in RA During the Forecast Period
  • Figure 33: Global (8MM) Sales Forecast by Country for RA in 2017 and 2027
  • Figure 34: Global (8MM) Sales Forecast for RA, by Class, in 2017 and 2027
  • Figure 35: Sales Forecast by Class for RA in the US in 2017 and 2027
  • Figure 36: Sales Forecast by Class for RA in the 5EU in 2017 and 2027
  • Figure 37: Sales Forecast by Class for RA in Japan in 2017 and 2027
  • Figure 38: Sales Forecast by Class for RA in Australia in 2017 and 2027
Note: Product cover images may vary from those shown
3 of 3
  • Abbvie Inc
  • Pfizer Inc
  • Amgen Inc
  • Johnson & Johnson
  • Merck & Co Inc/Merck Sharp & Dohme
  • Bristol-Myers Squibb Co
  • F Hoffman-La Roche Ltd
  • Genentech Ltd
  • Chugai Pharmaceutical Co Ltd
  • Biogen Inc
  • Eli Lilly and Co
  • UCB SA
  • Sanofi
  • Regeneron Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Gilead Science Inc
  • Galapagos NV
  • R-Pharm
  • Taisho Pharmaceutical Holdings Co Ltd
  • Can-Fite BioPharma Ltd
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Samsung Bioepis Co Ltd
  • Celltrion Inc
  • Sandoz Inc
Note: Product cover images may vary from those shown
Adroll
adroll